MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotech developing nanobody therapies for inflammatory diseases. Its lead candidate, sonelokimab, is in Phase 3 trials for hidradenitis suppurativa and psoriatic arthritis. With fast-track potential and a differentiated platform, MoonLake is a high-momentum biotech name in immunology.
最新股票文章

英伟达股票预测:第三方价格目标
自2025年年初以来,截至4月中旬,英伟达(NVDA)股价下跌约27.37%,但同比上涨26.48%。基于4月22日开盘价98.78美元,自1月初以来,英伟达股票波动显著,受到行业特定因素以及围绕美国贸易关税的更广泛股市不确定性影响。
17:42, 19 五月 2025


